The microalbumin test detects small amounts of albumin (protein) in urine — the earliest sign of diabetic kidney disease. Damaged kidneys allow albumin to leak into urine; the leak is detectable years before kidney function declines on standard tests like creatinine or eGFR. Early detection enables intervention that may slow or reverse progression. ADA recommends annual microalbumin testing for adults with type 2 diabetes from diagnosis; type 1 diabetes starting 5 years after diagnosis. Albumin-to-creatinine ratio (ACR) is the standard measure: under 30 mg/g normal, 30-300 microalbuminuria, over 300 macroalbuminuria. Results may vary day-to-day, so abnormal results should be confirmed with repeat testing 1-2 times over 3-6 months. Elevated microalbumin indicates early diabetic nephropathy and increased cardiovascular risk; standard action steps include ACE inhibitor or ARB therapy (reduces ACR 30-50%), SGLT2 inhibitor for kidney protection (CREDENCE, DAPA-CKD trials), aggressive blood pressure control (target under 130/80), tight glucose control, finerenone (Kerendia) for adults with T2D and CKD, weight loss if overweight, sodium reduction, modest protein moderation, and smoking cessation. Often reversible if caught early.
Albumin-to-Creatinine Ratio Categories
| ACR (mg/g) | Category | Stage | Action |
|---|---|---|---|
| under 30 | Normal | No diabetic kidney disease | Annual screening |
| 30-300 | Microalbuminuria | Early diabetic nephropathy | ACE/ARB; SGLT2i; tight control |
| over 300 | Macroalbuminuria | Overt diabetic nephropathy | Same + nephrology referral |
| over 3,000 | Severe albuminuria | Nephrotic-range proteinuria | Urgent nephrology referral |
Why Microalbumin Matters
- Earliest detectable sign of diabetic kidney damage.
- Years before creatinine or eGFR shows decline.
- Strong predictor of cardiovascular events independent of kidney function.
- Identifies adults who benefit most from ACE inhibitor/ARB therapy.
- Identifies adults who benefit most from SGLT2 inhibitors.
- Often reversible with early intervention — can return to normal.
- If untreated, progresses to macroalbuminuria, then to kidney failure.
- End-stage kidney disease (dialysis) is preventable through early screening and action.
How the Test Is Performed
- Random spot urine sample (most common).
- First morning urine often preferred (more concentrated).
- Lab measures albumin and creatinine concentrations.
- Calculates ACR (albumin/creatinine).
- Results typically available within 24-48 hours.
- 24-hour urine collection: alternative; less commonly used.
- Some labs offer “albumin only” but ACR is preferred.
- Point-of-care tests available at some clinics.
Factors That May Cause False-Positive Results
- Recent strenuous exercise (within 24 hours).
- Fever, acute illness.
- Urinary tract infection.
- Menstruation (avoid testing during).
- Heart failure decompensation.
- Severe hypertension (uncontrolled).
- Pregnancy (preeclampsia screening uses separate criteria).
- Recent high-protein meal.
- Repeat testing in 1-3 months to confirm persistent elevation.
Treatment for Microalbuminuria
- ACE inhibitors: lisinopril, ramipril, enalapril, benazepril — first-line.
- ARBs: losartan, valsartan, irbesartan, telmisartan — alternative for ACE intolerance.
- SGLT2 inhibitors: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana) — kidney protection.
- Finerenone (Kerendia): nonsteroidal mineralocorticoid receptor antagonist; for T2D + CKD.
- GLP-1 agonists: semaglutide (Ozempic), dulaglutide (Trulicity) — modest kidney benefit.
- Tight glucose control: A1C under 7%; modify based on comorbidities.
- Aggressive blood pressure: target under 130/80.
- Reduce sodium: under 2.3 g daily.
- Modest protein reduction: 0.8 g/kg body weight if not malnourished.
- Weight loss: 5-10% body weight if overweight.
- Smoking cessation: significantly reduces progression.
SGLT2 Inhibitors for Kidney Protection
- CREDENCE trial: canagliflozin reduced kidney failure by 32% in T2D + CKD.
- DAPA-CKD trial: dapagliflozin reduced kidney decline (including in non-diabetic CKD).
- EMPA-KIDNEY trial: empagliflozin reduced kidney progression.
- Recommended for adults with diabetes + microalbuminuria/CKD.
- Used in addition to (not instead of) ACE/ARB.
- Side effects: genital yeast infections, dehydration, rare diabetic ketoacidosis.
- Discontinue temporarily during acute illness or surgery.
- Monitor kidney function periodically.
Frequency Recommendations
- Adults with type 2 diabetes: annually from diagnosis.
- Adults with type 1 diabetes: annually starting 5 years after diagnosis.
- Pregnant women with diabetes: each trimester.
- Adults with microalbuminuria: every 6 months to monitor.
- Adults with macroalbuminuria: every 3-6 months.
- Adults on dialysis: ACR not routinely useful.
- Adults with recent abnormal result: repeat in 1-3 months to confirm persistence.
- Children with type 1 diabetes: start at age 11 or after 5 years of diabetes.
The Bottom Line
The microalbumin test detects small amounts of albumin in urine — the earliest sign of diabetic kidney disease. Damaged kidneys allow albumin to leak into urine; the leak is detectable years before kidney function declines on standard tests. Early detection enables intervention that may slow or reverse progression. ADA recommends annual microalbumin testing for adults with type 2 diabetes from diagnosis; type 1 diabetes starting 5 years after diagnosis. Albumin-to-creatinine ratio (ACR) is the standard measure: under 30 mg/g normal, 30-300 microalbuminuria (early diabetic nephropathy), over 300 macroalbuminuria (overt nephropathy). Abnormal results should be confirmed with repeat testing 1-2 times over 3-6 months. Factors causing false-positive: recent strenuous exercise, fever/illness, UTI, menstruation, severe hypertension. Elevated microalbumin indicates early diabetic nephropathy and increased cardiovascular risk. Treatment: ACE inhibitors (lisinopril, ramipril) or ARBs (losartan, valsartan) reduce ACR 30-50%; SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) for kidney protection (CREDENCE, DAPA-CKD, EMPA-KIDNEY trials); finerenone (Kerendia) for T2D + CKD; GLP-1 agonists (semaglutide, dulaglutide) for modest kidney benefit; aggressive glucose control (A1C under 7%); aggressive blood pressure (under 130/80); sodium reduction under 2.3 g daily; modest protein moderation (0.8 g/kg if not malnourished); weight loss 5-10% if overweight; smoking cessation. Often reversible if caught early — combined approach may return ACR to normal. End-stage kidney disease requiring dialysis is preventable through annual screening and early action. For adults with type 2 diabetes, microalbumin testing is among the most important annual screenings; insist on it as part of routine diabetes care. See our broader nephropathy symptoms guide for context.
